AlfaOlga/istock via Getty Images
Exploring Gene and Cell Therapy Integration in Pharmacies
Integrating gene and cell therapy in pharmacies ensures accessibility, personalized care, and effective management, enhancing patient outcomes.
After seeing promising results in cell and gene therapy clinical trials, cell and gene therapy is transforming patient care, offering new possibilities for treating diseases that previously had limited treatment options. As pharmacies integrate these therapies into their operations, they face challenges and opportunities.
In a recent conversation with Tracey James, RPh, Chief Operating Officer of Walgreens Enterprise Specialty, PharmaNewsIntelligence explored the impact of gene and cell therapy on pharmacy operations, the need for patient-centric engagement models, and the necessary adaptations for pharmacies to handle these intricate therapies effectively.
Patient-Centric Engagement in Gene and Cell Therapy
Customization is at the core of patient-centric engagement in gene and cell therapy. Walgreens recognizes the importance of multiple engagement channels, such as digital notifications, texting, and telehealth options, to meet patients on their terms and enhance their overall treatment experience.
"Each patient's journey will be unique; therefore, pharmacies will need to be flexible and nimble enough to create a customized journey for each patient," emphasized James.
Challenges and Opportunities in Delivering Patient Care
James highlighted the challenges posed by gene and cell therapies and the corresponding opportunities for pharmacies. Regarding specialized handling requirements, "having the right infrastructure and a dedicated, specially trained team to manage these therapies is critical,” emphasized James.
Additionally, addressing insurance coverage, reimbursement, and affordability for patients receiving high-cost therapies is crucial.
Conversely, pharmacies have several opportunities to expand their role in patient care.
"Pharmacies will be integral in providing comprehensive care by offering a personalized treatment journey, including consultations, education, and support specific to gene and cell therapies," James mentioned.
Advanced technologies can aid pharmacies in managing and tracking these specialized therapies, ensuring proper handling, adherence, and patient monitoring. Collaboration among healthcare providers, treatment centers, manufacturers, and payers will be essential to ensure a seamless treatment journey for patients.
Adapting Expertise, Technology, and Overall Model for Personalized Medicine
The emergence of personalized medicine necessitates adaptations in expertise, technology, and the overall model of pharmacies.
"Pharmacies must employ advanced software to track and report metrics to all parties involved in the patient's treatment journey,” James explained, highlighting the need for robust data management systems.
Pharmacists may require additional training to interpret genetic and molecular information to tailor medications.
Additionally, James stressed the importance of fostering strong relationships with healthcare providers, treatment centers, manufacturers, and payers. Collaboration and continuous communication among various stakeholders is vital — seamless communication ensures the accurate and timely delivery of personalized treatments.
James pointed out that pharmacies must also adopt patient-centric approaches, engaging patients and their caregivers to understand their customized treatment plans and the steps involved in their treatment journey.
Reshaping the Role of Pharmacies in the Healthcare Ecosystem
Pharmacies need specialized infrastructure to handle gene and cell therapies effectively, including temperature-controlled storage units and dedicated spaces. Specialized expertise, a holistic patient management approach, technology integration, collaborative partnerships, and outcomes monitoring are essential for pharmacies to adapt to this evolving landscape.
"Pharmacies should be the epicenter for gene and cell therapies, orchestrating all the different facets of patients' journeys," declared James.
Necessary Changes for Effective Handling of Gene and Cell Therapies
Pharmacies are confronted with the imperative need for substantial transformations to manage gene and cell therapies for specialty patients adeptly. James shared that the landscape of necessary changes encompasses regulatory compliance, infrastructure and facilities, advanced training and education, technology integration, collaborative partnerships, conversations on reimbursement, and financial strategies.
Regulatory Compliance
“Pharmacies need to navigate stringent regulations governing the storage, handling, and dispensing of gene and cell therapies,” suggested James, stressing the critical role of regulatory compliance. “Adhering to quality assurance and safety protocols is paramount.”
Infrastructure and Facilities
“Pharmacies must invest in facilities equipped to handle gene and cell therapies' unique storage and preparation requirements,” said James, highlighting the need for specialized infrastructure. “This involves implementing temperature-controlled storage units and dedicated spaces for preparation.”
Advanced Training and Education
“Pharmacists and pharmacy staff must undergo extensive training to grasp the complexities of gene and cell therapies,” stated James, underscoring the importance of education and training. “This includes understanding administration protocols, potential adverse effects, and patient monitoring.”
Technology Integration
“Implementing advanced technology systems for inventory management, patient data tracking, and communication with healthcare providers is crucial in ensuring seamless operations,” James noted.
Collaborative Partnerships
“Establishing strong partnerships with treatment centers, healthcare providers, pharmaceutical manufacturers, and insurers is essential for a seamless experience and coordinated care delivery,” highlighted James.
Reimbursement and Financial Strategies
“Given the high cost of these therapies, pharmacies need strategies to navigate reimbursement challenges, assist patients with financial assistance programs, and help ensure a clear path to payment,” James said.
Ensuring Patient Engagement in Gene and Cell Therapy Services
Patient engagement remains a critical aspect of gene and cell therapy services, and pharmacies play a pivotal role in achieving this.
"Setting clear expectations with patients and utilizing digital modes of communication for greater ease of patient use is crucial," emphasized James.
Case management was also highlighted as critical in overseeing various aspects of a patient's care journey: "Case managers act as advocates for patients, ensuring seamless coordination from initial assessment to treatment and follow-up care," explained James.
Additionally, pharmacies must provide ongoing education, support, and communication to empower patients to participate actively in their treatment plans.
As gene and cell therapies revolutionize patient care, pharmacies must adapt to meet the unique demands of these therapies. The insights shared by James shed light on the challenges and opportunities that lie ahead for pharmacies in integrating gene and cell therapies into their operations.
By embracing patient-centric engagement models, adapting expertise and technology, and reshaping their role in the healthcare ecosystem, pharmacies can deliver personalized, high-quality care and drive positive patient outcomes.
And as pharmacies navigate the complexities of gene and cell therapies, they can transform patient care and contribute to advancing healthcare in the age of personalized medicine.
